Protalix Biotherapeutics Inc (PLX)

Currency in USD
3.005
-0.015(-0.50%)
Real-time Data·
PLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.9203.140
52 wk Range
1.6503.190
Key Statistics
Prev. Close
3.02
Open
2.97
Day's Range
2.92-3.14
52 wk Range
1.65-3.19
Volume
1.01M
Average Volume (3m)
869.91K
1-Year Change
69.774%
Book Value / Share
1,00
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PLX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.000
Upside
+299.33%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.000
(+299.33% Upside)

Protalix Biotherapeutics Inc Earnings Call Summary for Q3/2026

  • Protalix posted Q3 EPS of $0.05 vs. expected loss of $0.05; revenue hit $21.93M, nearly double the $11.74M forecast, yet shares fell 4.67%.
  • Revenue rose 22.3% YoY to $21.93M driven by Elfabrio sales to Chiesi; gross margin expanded to 64.0% from 52.5% on improved product mix.
  • Cash position strengthened to $48.5M with zero debt; R&D spending jumped 53.3% to $6.9M as company advances PRX-115 gout treatment program.
  • Management expects 'good overall 2026' from Elfabrio momentum; PRX-115 Phase II enrollment to finish Q4 2026 with results due H2 2027.
  • Full-year 2026 and 2027 guidance deferred to March 2027; CEO cited $3.2B Fabry market opportunity by 2031 for Elfabrio via Chiesi partnership.
Last Updated: 2026/11/10, 15:44
Read Full Transcript

Earnings

Latest Release
Nov 10, 2026
EPS / Forecast
0,05 / -0,05
Revenue / Forecast
21,93M / 11,74M
EPS Revisions
Last 90 days

PLX Income Statement

Compare PLX to Peers and Sector

Metrics to compare
PLX
Peers
Sector
Relationship
P/E Ratio
12.8x35.9x−0.2x
PEG Ratio
0.050.000.00
Price/Book
3.3x2.3x2.6x
Price / LTM Sales
3.1x5.8x2.7x
Upside (Analyst Target)
294.7%91.8%69.6%
Fair Value Upside
Unlock7.5%11.7%Unlock

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

Employees
226

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7,85M9,31%23,71M
Other Institutional Investors
16,43M19,48%49,61M
Public Companies & Retail Investors
60,04M71,21%181,32M
Total
84,32M100,00%254,64M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Hold Alapkezelo Zrt4,93%4 157 79112 557
BlackRock, Inc.4,80%4 046 65012 221

FAQ

What Is the Protalix (PLX) Stock Price Today?

The Protalix stock price today is 3,005 USD.

What Stock Exchange Does Protalix Trade On?

Protalix is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Protalix?

The stock symbol for Protalix is "PLX."

What Is the Protalix Market Cap?

As of today, Protalix market cap is 252,960M USD.

What Is Protalix's Earnings Per Share (TTM)?

The Protalix EPS (TTM) is 0,26.

When Is the Next Protalix Earnings Date?

Protalix will release its next earnings report on Mar 31, 2027.

From a Technical Analysis Perspective, Is PLX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Protalix Stock Split?

Protalix has split 2 times.

How Many Employees Does Protalix Have?

Protalix has 226 employees.

What is the current trading status of Protalix (PLX)?

As of Nov 19, 2026, Protalix (PLX) is trading at a price of 3,005 USD, with a previous close of 3,020 USD. The stock has fluctuated within a day range of 2,920 USD to 3,140 USD, while its 52-week range spans from 1,650 USD to 3,190 USD.

What Is Protalix (PLX) Price Target According to Analysts?

The average 12-month price target for Protalix is 12,000 USD, with a high estimate of 12 USD and a low estimate of 12 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +299,33% Upside potential.

What Is the PLX Premarket Price?

PLX's last pre-market stock price is 3,000 USD. The pre-market share volume is 2 820,000, and the stock has decreased by -0,020, or -0,660%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.